Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation

Anthony Mato • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Checkpoint inhibitors Pembrolizumab Ublituximab Umbralisib

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, highlights data from the Phase I/II triple therapy study of umbralisib and ublituximab (‘U2’) combined with checkpoint inhibition in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Anthony Mato

1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals